Advertisement

Topics

Tyme, Inc. Company Profile

00:17 EST 15th December 2018 | BioPortfolio

Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic characteristics of cancer cells as well as activating the endogenous immune response against tumors. Tyme's approach is hypothesized to permit selective elimination of cancer cells, while simultaneously improving patients' well-being, particularly with respect to pain severity and functional independence.


News Articles [21 Associated News Articles listed on BioPortfolio]

Tyme Technologies: Our Take On This $3 Biotech Concern

Tyme Technologies, Inc. Set to Join Russell 3000® Index

NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set to...

Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019

SM-88 to be included in pivotal Precision Promise pancreatic cancer trial led by Pancreatic Cancer Action Network (PanCAN) expected to commence in the first half of 2019 Interim data for SM-88 from ...

Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019

NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical a...

Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer

NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target ...

Tyme Technologies, Inc. to Present at the Evercore ISI, HealthconX Conference on November 27th

NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today annou...

Tyme, Inc. to Present at the Stifel 2018 Healthcare Conference on November 13th

NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical stage biotechnology company developing cancer therapeutics for pancreatic, prostate and sarcoma tumors...

Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors

Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors James Biehl appointed as Chief Legal Officer of Tyme; to step down from the board of d...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).

Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is s...

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Tyme, Inc.

Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of wha...

Tyme Technologies, Inc.

Tyme, Inc. is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme, Inc. is the origi...

Tyme Technologies Inc.

Tyme Technologies, Inc.

More Information about "Tyme, Inc." on BioPortfolio

We have published hundreds of Tyme, Inc. news stories on BioPortfolio along with dozens of Tyme, Inc. Clinical Trials and PubMed Articles about Tyme, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tyme, Inc. Companies in our database. You can also find out about relevant Tyme, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record